Join the Class Action Lawsuit Against Regeneron Pharmaceuticals: What Investors Should Know

Investors and Class Action Against Regeneron Pharmaceuticals

In a recent announcement, the Rosen Law Firm, an esteemed global investor rights organization, has brought attention to a significant opportunity for investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This relates to a securities fraud class action lawsuit where investors who purchased securities of the company between November 2, 2023, and October 30, 2024 are reminded that March 10, 2025, is a critical date to apply to lead the class action.

Why This Lawsuit Matters

The class action lawsuit has been filed, and those who bought Regeneron securities during the specified period may be eligible for compensation without any immediate out-of-pocket expenses, thanks to a contingency fee arrangement. This means that the legal fees will be covered by the lawsuit’s outcomes, allowing investors to join the case without financial strain.

Taking Action

For those interested in joining the action, the process is straightforward. Investors can visit the Rosen Law Firm website at rosenlegal.com or reach out directly by calling Phillip Kim, Esq. at 866-767-3653. It is essential that investors act quickly, as the deadline to move to appoint a lead plaintiff is fast approaching.

The What and Why of the Lawsuit

The crux of the lawsuit revolves around allegations that throughout the class action period, Regeneron allegedly made false and misleading statements, which significantly misrepresented the company’s financial health and business operations. The complaint indicates that the company:

1. Conditioned Credit Card Fees: Regeneron allegedly paid credit card fees to distributors under the agreement that they would not charge more to consumers using credit cards to purchase `Eylea`, a prominent Regeneron drug.
2. Price Concessions: These payments were purportedly made to subsidize the purchase prices for consumers, thus misleadingly inflating the reported sales of Eylea and causing investors to suffer damages when the truth came to light.
3. Overstating Sales Prices: The lawsuit claims that Regeneron failed to accurately report these payments and concessions, resulting in an overstated Average Sales Price (ASP) reported to federal agencies, which violates the False Claims Act.

These deceptive practices, when uncovered, imply that the company's optimistic statements about its business could not be justified. Therefore, the investors faced losses when the accurate information began to circulate in the market, causing a decline in stock prices.

Choosing the Right Counsel

In an environment where many notice-serving firms lack adequate experience or resources in leading securities litigation, the Rosen Law Firm highlights the importance of aligning with qualified counsel. Their track record speaks for itself, boasting a number of successful securities class action settlements over the years, including a record settlement involving a Chinese company. The firm's commitment to protecting investor rights and their robust history makes them a reliable choice for those looking to navigate this potential legal battle.

Investment Recovery Potential

While the class has yet to be certified, investors are encouraged to consider their options. They can either join as a participant without any further action or proceed to designate a lead plaintiff. Remember, an investor's potential to benefit from any future recovery does not hinge on taking the lead role in the suit, giving them some flexibility on how to proceed.

Conclusion

For Regeneron investors, this moment represents a critical opportunity to seek justice and possible compensation from what has been alleged as deceptive practices by the company. The Rosan Law Firm stands ready to assist those who are affected, inviting them to respond decisively by the March 10, 2025, deadline. Stay informed and don’t hesitate to leverage this chance to assert your rights as an investor.

For more details, be sure to follow updates on LinkedIn or Twitter from the Rosen Law Firm to stay informed of developments regarding the case.